Brief: Alzamend Neuro Announces Initiation Of Phase IIA Multiple Ascending Dose Clinical Trial For AL001 Treatment Of Dementia Related To Alzheimer’S
05/05/2022 13:42
May 5 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO ANNOUNCES INITIATION OF PHASE IIA MULTIPLE
ASCENDING DOSE CLINICAL TRIAL FOR AL001 TREATMENT OF DEMENTIA
RELATED TO ALZHEIMER’S
* ALZAMEND NEURO INC - TOPLINE DATA EXPECTED IN DECEMBER
2022
Source text for Eikon: ID:nBw8hSyXTa
Further company coverage: ALZN.O
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview